Chelsea Therapeutics

FDA approves Northera to treat neurogenic orthostatic hypotension

Wednesday, February 19, 2014

The FDA has approved Northera capsules (droxidopa) for the treatment of neurogenic orthostatic hypotension (NOH). NOH is a rare, chronic and often debilitating drop in blood pressure upon standing that is associated with Parkinson’s disease, multiple-system atrophy and pure autonomic failure.  

[Read More]